Eli Lilly | LLY - تكلفة المبيعات





تكلفة المبيعات تغيير تاريخ
AbbVie USD 4.29B 73M 2026-06
Abbott USD 5.94B 642M 2026-06
ALKERMES USD 120.7M 47.44M 2026-06
Amgen USD 1.87B 271M 2026-06
AstraZeneca USD 2.52B 2.73B 2026-06
Baxter International USD 1.93B 118M 2026-06
Biogen USD 945.1M 147.6M 2026-06
Bristol-Myers Squibb USD 7.89B 4.03B 2026-06
Coherus Biosciences USD 4.04M 324K 2025-12
Drreddys Laboratories INR 32.13B 8.34B 2026-03
Eli Lilly USD 3.27B 309M 2026-06
Gilead Sciences USD 1000M 445M 2026-06
GlaxoSmithKline GBP 2.07B 192M 2026-06
Glaxosmithkline GBP 1.88B 1.6B 2026-03
J&J USD 8B 67M 2026-06
Medtronic USD 3.83B 26M 2026-06
Merck USD 3.14B 200M 2026-06
Neurocrine Biosciences USD 39.4M 25.6M 2026-06
Novartis USD 3.71B 251M 2026-06
Novartis USD 3.46B 83M 2026-03
Novo Nordisk DKK 17.1B 3.5B 2026-06
Perrigo USD 708.9M 65.2M 2026-06
Pfizer USD 4.09B 498M 2026-06
Phibro Animal Health USD 240.42M 2.58M 2025-12
Prestige Brands USD 135.22M 5.54M 2026-06
Regeneron Pharmaceuticals USD 576.5M 92.9M 2026-06
Roche Holding CHF 7.85B 630M 2026-06
Sanofi EUR 3.02B 656M 2026-06
Sanofi EUR 3.14B 618M 2026-03
United Therapeutics USD 99.5M 33.9M 2026-06
Zoetis USD 704M 32M 2026-06